{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:02:05Z","timestamp":1787785325493,"version":"build-2784847793"},"reference-count":27,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:p>\n                    Poor access to HIV viral load (VL) testing prevents the timely monitoring of HIV treatment adherence and efficacy. Factors enabling clinical benefits of VL testing when added to local standards of care, can inform the development of more cost-effective routine VL scale-up plans. We compared antiretroviral therapy (ART) switch practices in 13 clinics across 6 countries, with full (\n                    <jats:italic toggle=\"yes\">N<\/jats:italic>\n                    \u2009=\u20098), phasing-in (\n                    <jats:italic toggle=\"yes\">N<\/jats:italic>\n                    \u2009=\u20093) or no onsite access (\n                    <jats:italic toggle=\"yes\">N<\/jats:italic>\n                    \u2009=\u20092) to VL. The analysis used data from the Pan-African Studies to Evaluate Resistance (PASER), observing virological and drug resistance outcomes among adults receiving first- or second-line ART between 2008 and 2015. Study plasma viral load (sVL) determined at baseline, every 12 months thereafter and at the time of switch served for retrospectively validating switch decisions, categorized into \u201cnecessary,\u201d \u201cunnecessary,\u201d and \u201cmissed.\u201d Virological failure was defined as two consecutive sVL \u22651,000 HIV-RNA copies\/mL. One thousand nine hundred ninety-five of the 2,420 (82.4%) study participants had continuous virological suppression during the median 30 months of follow-up. Among the 266 virological failures (11.0%), the proportion of necessary switches were similar in clinics with full (37%), phasing-in (25%), or no access (39%) to local VL testing. Documented utilization of local VL results for the switch decision was associated with higher percentage of necessary switch (87.6% vs. 67.9%). Shorter time to necessary switch was associated with higher rates of long-term virological suppression, regardless of access to local viral load. Availability of HIV VL testing capacity does not systematically result in adequate switch practices or better virological outcomes. Systems supporting sufficient test demand execution, and actual utilization of results for patient management need strengthening.\n                  <\/jats:p>","DOI":"10.1089\/aid.2020.0049","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T03:10:09Z","timestamp":1595992209000},"page":"918-926","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Access to HIV Viral Load Testing and Antiretroviral Therapy Switch Practices: A Multicountry Prospective Cohort Study in Sub-Saharan Africa"],"prefix":"10.1177","volume":"36","author":[{"given":"Pascale","family":"Ondoa","sequence":"first","affiliation":[{"name":"African Society for Laboratory Medicine, Addis Ababa, Ethiopia."},{"name":"Amsterdam Institute for Global Health and Development, Academic Medical Center, Department of Global Health, University of Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea A.","family":"Kim","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA."},{"name":"Los Angeles County Public Health Department, Los Angeles, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Sonia","family":"Boender","sequence":"additional","affiliation":[{"name":"Amsterdam Institute for Global Health and Development, Academic Medical Center, Department of Global Health, University of Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Kroeze","sequence":"additional","affiliation":[{"name":"Amsterdam Institute for Global Health and Development, Academic Medical Center, Department of Global Health, University of Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Wiener","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariette","family":"Botes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Botes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alani Sulaimon","family":"Akanmu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleiman","family":"Akanmu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Wellington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareth","family":"Siwale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishor","family":"Mandaliya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cissy","family":"Kityo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman E.F.","family":"Labib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titilope A.","family":"Adeyemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Rinke de Wit","sequence":"additional","affiliation":[{"name":"Amsterdam Institute for Global Health and Development, Academic Medical Center, Department of Global Health, University of Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Nkengasong","sequence":"additional","affiliation":[{"name":"Africa Centers for Disease Control, Addis Ababa, Ethiopia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"key":"e_1_3_6_2_2","volume-title":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. World Health Organization, Geneva, Switzerland, 2013."},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00087-9"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw218"},{"key":"e_1_3_6_5_2","first-page":"1761","article-title":"Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa","volume":"25","author":"Keiser O","year":"2013","unstructured":"Keiser O, , Chi BH, , Gsponer T, et al.: Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. NIH Public Access, 2013; 25:1761\u20131769.","journal-title":"NIH Public Access"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx125"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix404"},{"key":"e_1_3_6_8_2","unstructured":"UNAIDS Data. 2018. Joint United Nations Programme on HIV\/AIDS Geneva Switzerland. Available at www.unaids.org\/sites\/default\/files\/media_asset\/unaids-data-2018_en.pdf"},{"key":"e_1_3_6_9_2","unstructured":"UNAIDS. 90-90-90: An Ambitious Treatment Target to Help End the AIDS Epidemic. Geneva: UNAIDS 2014."},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6547a2"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.4102\/ajlm.v3i1.127"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.4102\/ajlm.v3i1.126"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ssmph.2016.10.003"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2017.0134"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyq192"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ656"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001801"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw219"},{"key":"e_1_3_6_19_2","volume-title":"Antiretroviral therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Aapproach","author":"World Health Organization","year":"2006","unstructured":"World Health Organization: Antiretroviral therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Aapproach. World Health Organization, Geneva, Switzerland, 2006."},{"key":"e_1_3_6_20_2","volume-title":"Antiretroviral Therapy for HIV Infection in Adults and Adolescents","author":"World Health Organization","year":"2011","unstructured":"World Health Organization: Antiretroviral Therapy for HIV Infection in Adults and Adolescents. World Health Organization, Geneva, Switzerland, 2011."},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2009.11.011"},{"key":"e_1_3_6_22_2","first-page":"132","article-title":"2017 Update of the drug resistance mutations in HIV-1","volume":"24","author":"Wensing AM","year":"2017","unstructured":"Wensing AM, , Calvez V, , G\u00fcnthard HF, et al.: 2017 Update of the drug resistance mutations in HIV-1. Top Antivir Med, 2017; 24:132\u2013133.","journal-title":"Top Antivir Med"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198686"},{"key":"e_1_3_6_24_2","unstructured":"LabCoP cookbook recipe #2: test result utilization. Available at www.aslm.org\/aslms-laboratory-systems-strengthening-community-practice-labcop-2 accessed April17 2019."},{"key":"e_1_3_6_25_2","unstructured":"van Nieuwenhuizen B: Barriers preventing recommended practices surrounding viral load testing for HIV patients in Uganda. Master thesis in Global Health Vrije Universiteit Amsterdam 2016. Student number 2560227."},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2018.1563280"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25008"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25010"}],"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/aid.2020.0049","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2020.0049","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2020.0049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:14:56Z","timestamp":1777367696000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/aid.2020.0049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1089\/aid.2020.0049"],"URL":"https:\/\/doi.org\/10.1089\/aid.2020.0049","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}